A comprehensive view of Diabetes. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Abbott’s FreeStyle Libre 3 continuous glucose monitor for diabetes management in patients four years of age and older; device is smallest, thinnest CGM monitor in the world, will be available at pharmacies later in 2022

Long COVID may be associated with patients with high viral loads, autoantibodies, reactivation of Epstein-Barr virus, type 2 diabetes; data suggests administering antivirals after diagnosis may rapidly eliminate virus, prevent long-term symptoms: study

2022 Pharmapack Award winners include reusable Aria Smart Autoinjector, Aidaptus disposable auto-injector, SKYTROFA Auto-Injector, Autotest COVID-VIRO ALL IN, TouStar reusable insulin pens, and YpsoMate On, the world’s first pre-filled auto-injector

Global negative pressure wound therapy market projected to grow to US$3.1B by 2026, with CAGR growth of 6.1% from 2022 to 2026; growth driven by rise in chronic diseases and diabetes, growing aging population, with US market reaching US$1.2B in 2022

LabCorp launches at-home diabetes screening kit in US with 97% accuracy co-developed with device owner Weavr Health; LabCorp only commercial lab offering the test, which measures hemoglobin A1c from a small blood sample

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count